Figures & Tables
Tables
- TABLE. Antiretrovirals With Long-Acting Potential: Illustrative Examples from Different Drug Classes
Drug Class ARV Name Development Phase Company Non-Nucleoside
Reverse Transcriptase InhibitorRilpivirine Phase III injectable (oral agent approved) Janssen Integrase Inhibitor Cabotegravir Phase III injectable ViiV Nucleoside/Nucleotide
Reverse Transciptase
Inhibitor (NRTI)EFdA Phase I Merck Tenofovir alafenamide fumarate (TAF) Preclinical implant (oral agent approved) Gilead GS-9131 Preclinical/Phase I Gilead Capsid Inhibitor GS-CA1 Preclinical Gilead
In this issue
Statistics from Altmetric.com
Jump to section
- Article
- WHY WE NEED LONG-ACTING ANTIRETROVIRALS
- TANGIBLE PROGRESS ON A 1- OR 2-MONTH INJECTABLE
- NEW ARVS MAY HELP OVERCOME THESE DOWNSIDES
- BROADLY NEUTRALIZING ANTIBODIES: A POSSIBLE ALTERNATIVE TO LONG-ACTING ARVS FOR PREVENTION
- IMPLANTS THAT ARE EASIER TO IMPLEMENT: BIODEGRADABLE AND REFILLABLE APPROACHES
- IMPROVED INJECTION APPROACHES: SIMPLIFYING ADMINISTRATION, REDUCING COST AND DISCOMFORT
- COLLABORATIVE EFFORTS TO ADVANCE NEW ARVS
- CONTINUING DOWN THE ROAD TO ULTIMATE SUCCESS
- Acknowledgments
- Notes
- REFERENCES
- Figures & Tables
- Info & Metrics
- Comments
Related Articles
Cited By...
- No citing articles found.